Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Item
http://www.wikidata.org/entity/Q39260796
Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.Treatment of Helicobacter pylori infection 2017.Empiric H. pylori therapy-10-day concomitant, bismuth quadruple or 14-day triple therapy: none is best.Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori.New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin.Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.Treatment of Helicobacter pylori infection: A clinical practice update.Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea.Letter: levofloxacin resistance - a challenge for treatment of Helicobacter pylori infection. Authors' reply.Which Regimens Should Be Used and Which Rejected for the Treatment of Helicobacter pylori?Efficacy of two different dosages of levofloxacin in curing Helicobacter pylori infection: A Prospective, Single-Center, randomized clinical trial.Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication.Comparison between different first-line therapy protocols in eradicating Helicobacter pylori in a region with high clarithromycin resistance.
P2860

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Item
http://www.wikidata.org/entity/Q39260796
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Concomitant, bismuth quadruple ...... open-label, randomised trial.
@en
Concomitant, bismuth quadruple ...... open-label, randomised trial.
@nl
type
label
Concomitant, bismuth quadruple ...... open-label, randomised trial.
@en
Concomitant, bismuth quadruple ...... open-label, randomised trial.
@nl
prefLabel
Concomitant, bismuth quadruple ...... open-label, randomised trial.
@en
Concomitant, bismuth quadruple ...... open-label, randomised trial.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Concomitant, bismuth quadruple ...... open-label, randomised trial.
@en
P2093
P304
P31
P356
10.1016/S0140-6736(16)31409-X
P407
P433
P478
P50
P577
P698
P921